ORMP

Oramed Pharmaceuticals Inc. - 10-Q Summary (Period Ended May 31, 2009)

Business Context and Reporting Period

Oramed Pharmaceuticals Inc. is a development-stage company focused on the research and development of innovative pharmaceutical solutions, primarily an orally ingestible insulin pill for diabetes treatment. The company also explores rectal application of insulin and other polypeptides. This report covers the nine-month period ended May 31, 2009. The company has not yet realized any revenues from planned operations.

Key Financial Metrics

Note: The company reported no debt obligations on the balance sheet as of May 31, 2009, other than accounts payable and accrued expenses.

Material Changes vs. Prior Period

• Increased Operating Loss: The net loss increased by approximately 56% compared to the prior year period, driven primarily by a 121% increase in Research and Development (R&D) expenses ($1.45M vs. $0.66M).
• R&D Expense Growth: The rise in R&D costs is attributed to increased purchases of materials, expanded clinical trial activities, and higher patent-related costs. Stock-based compensation within R&D also increased.
• Asset Reduction: Total assets decreased by approximately $2.16 million. This is largely due to the liquidation of short-term investments ($2.73M) which were sold during the period, offset by an increase in cash balances.
• Liability Reduction: Current liabilities decreased by roughly $439,000, primarily due to the reduction in accounts payable and accrued expenses.

Outlook, Risks, and Management Commentary

• Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern. The company has an accumulated deficit of $9.6 million and negative cash flow from operations. With estimated spending commitments of $4.7 million for the next twelve months and only $3.2 million in cash, the company lacks sufficient resources to meet liquidity requirements through May 31, 2010.
• Financing Needs: The company is actively evaluating financing alternatives, including public or private equity fundraising, to fund future R&D and administrative expenses. There is no assurance that financing will be secured.
• Clinical Progress: The company is conducting non-FDA approved Phase 2B studies for its oral insulin capsule in South Africa and considering trials in India. A Phase 1A study for an insulin suppository was completed in South Africa in February 2009.
• Internal Controls: Management identified a material weakness in internal controls over financial reporting due to a lack of segregation of duties, as the CFO performs all accounting functions without independent checks.
• Related Party Transactions: Significant agreements exist with Hadasit Medical Services (a related party involving a director/officer) for clinical trial services, with total consideration of $400,000 under recent agreements.

Key Facts for Investor Verification

• Liquidity Runway: Verify the company's ability to secure the approximately $1.5 million funding gap required to operate for the next 12 months given the "Going Concern" warning.
• Clinical Trial Status: Confirm the timeline and results of the ongoing Phase 2B trials in South Africa and the potential for FDA IND filing.
• Related Party Payments: Review the terms and payment schedules of the agreements with Hadasit Medical Services, noting the involvement of company directors.
• Internal Control Remediation: Assess the progress made in addressing the material weakness regarding segregation of duties in financial reporting.
• Stock-Based Compensation: Monitor the impact of stock option grants and forfeitures on future expense recognition and dilution.